연구성과로 돌아가기
2023 연구성과별 연구자 정보 (1760 / 2675)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis | Izumi, Namiki | Izumi, N | 16 | Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Tokyo, Japan | daniel_huang@nus.edu.sg;nobuharu.tamaki@gmail.com;psyoung0419@gmail.com;kurosaki@musashino.jrc.or.jp;h.marusawa@osaka-med.jrc.or.jp;matoshi@matsuyama.jrc.or.jp;Masachan44@gmail.com;laboratory@matsue.jrc.or.jp;kobashi0584@gmail.com;furuta-k@masuda.jrc.or.jp;izumi012@musashino.jrc.or.jp;beomkkim@yuhs.ac;sinndhn@hanmail.net; | |||||
| Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis | Kim, Beom Kyung | Kim, BK | 17 | 교신저자 | Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea | I-5501-2015 | Kim, Kyung | 0000-0002-5363-2496 | Kim, Beom Kyung | daniel_huang@nus.edu.sg;nobuharu.tamaki@gmail.com;psyoung0419@gmail.com;kurosaki@musashino.jrc.or.jp;h.marusawa@osaka-med.jrc.or.jp;matoshi@matsuyama.jrc.or.jp;Masachan44@gmail.com;laboratory@matsue.jrc.or.jp;kobashi0584@gmail.com;furuta-k@masuda.jrc.or.jp;izumi012@musashino.jrc.or.jp;beomkkim@yuhs.ac;sinndhn@hanmail.net; |
| Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis | Kim, Beom Kyung | Kim, BK | 17 | 교신저자 | Yonsei Univ, Coll Med, Dept Internal Med, 50-1 Yonsei Ro, Seoul 03722, South Korea | I-5501-2015 | Kim, Kyung | 0000-0002-5363-2496 | Kim, Beom Kyung | daniel_huang@nus.edu.sg;nobuharu.tamaki@gmail.com;psyoung0419@gmail.com;kurosaki@musashino.jrc.or.jp;h.marusawa@osaka-med.jrc.or.jp;matoshi@matsuyama.jrc.or.jp;Masachan44@gmail.com;laboratory@matsue.jrc.or.jp;kobashi0584@gmail.com;furuta-k@masuda.jrc.or.jp;izumi012@musashino.jrc.or.jp;beomkkim@yuhs.ac;sinndhn@hanmail.net; |
| Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis | Sinn, Dong Hyun | Sinn, DH | 18 | 교신저자 | Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Med, Seoul, South Korea | JAC-4247-2023 | Sinn, Dong | daniel_huang@nus.edu.sg;nobuharu.tamaki@gmail.com;psyoung0419@gmail.com;kurosaki@musashino.jrc.or.jp;h.marusawa@osaka-med.jrc.or.jp;matoshi@matsuyama.jrc.or.jp;Masachan44@gmail.com;laboratory@matsue.jrc.or.jp;kobashi0584@gmail.com;furuta-k@masuda.jrc.or.jp;izumi012@musashino.jrc.or.jp;beomkkim@yuhs.ac;sinndhn@hanmail.net; | ||
| Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis | Sinn, Dong Hyun | Sinn, DH | 18 | 교신저자 | Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Med, 81 Irwon Ro, Seoul 06351, South Korea | JAC-4247-2023 | Sinn, Dong | daniel_huang@nus.edu.sg;nobuharu.tamaki@gmail.com;psyoung0419@gmail.com;kurosaki@musashino.jrc.or.jp;h.marusawa@osaka-med.jrc.or.jp;matoshi@matsuyama.jrc.or.jp;Masachan44@gmail.com;laboratory@matsue.jrc.or.jp;kobashi0584@gmail.com;furuta-k@masuda.jrc.or.jp;izumi012@musashino.jrc.or.jp;beomkkim@yuhs.ac;sinndhn@hanmail.net; | ||
| Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) | Lau, George | Lau, G | 1 | AAQ-2085-2021 | Lau, George | |||||
| Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) | Cheng, Ann-Lii | Cheng, AL | 2 | ACM-0936-2022 | Cheng, Ann-Lii | |||||
| Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) | Sangro, Bruno | Sangro, B | 3 | AFW-4106-2022 | Sangro, Bruno | |||||
| Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) | Kudo, Masatoshi | Kudo, M | 4 | AAA-9744-2019 | Kudo, Masatoshi | |||||
| Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) | Kelley, Robin Kate | Kelley, RK | 5 | |||||||
| Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) | Tak, Won Young | Tak, WY | 6 | |||||||
| Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) | Gasbarrini, Antonio | Gasbarrini, A | 7 | AAB-8487-2019 | Gasbarrini, Antonio | |||||
| Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) | Reig, Maria | Reig, M | 8 | |||||||
| Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) | Lim, Ho Yeong | Lim, HY | 9 | KBA-8868-2024 | Lim, Ho Yeong | |||||
| Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) | Tougeron, David | Tougeron, D | 10 | ABF-3217-2020 | tougeron, david |
페이지 이동: